Shots: The P-I dose-escalation study will assess the safety, tolerability, and preliminary efficacy of DS-1055 in adult patients with r/r advanced or metastatic head and neck, gastric and esophageal cancers, and other tumor types The focus of the study is to determine the maximum tolerated dose and recommended dose of DS-1055 for further study and […]Read More
Shots: Scenic to receive ~$375M that includes up front, milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies selected by Genentech The collaboration allows the Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will leverage […]Read More
Shots: Wigen to transfer its 50% interest in four drugs WJ1024/WJ1075, WJ05129, APL1898, and WJ13404 to Junshi. Wigen to receive $5.3M up front, $64.3M as milestones, and 50% on the net profit of the therapies Junshi to get WW exclusive rights for the production and commercialization of these drugs and will be responsible for clinical […]Read More
Shots: Kite enters into a two-year research collaboration and license agreement with HiFiBiO to discover novel targets and Abs against AML HiFiBiO will receive an up front and will utilize its technology platform to identify novel AML targets and anti-AML specific Abs to support Kite’s development of cell therapies Kite to get an exclusive option […]Read More
Shots: Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on […]Read More
Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected […]Read More
Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund […]Read More
Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs for the treatment of ALS and FTLD The collaboration integrates Yumanity’s drug discovery platform with Merck’s development and commercialization expertise in neuroscience Yumanity and […]Read More
Shots: Sorrento to get access to plasma containing anti-COVID-19 Abs for identifying and produce mAbs with neutralizing activity against SARS-CoV-2. The company expects to commence the P-I study of triple Ab combination therapy in Q3’20 The focus of the collaboration is to jointly develop Ab cocktail which will act as a protective shield against COVID-19 […]Read More
Shots: Bemcentinib has been selected as the first potential treatment to be fast-tracked under UK’s P-II ACCORD program that rapidly evaluates bemcentinib’s effectiveness in hospitalized UK NHS patients with COVID-19 The study will commence testing of bemcentinib vs SOC in 120 patients across 6 UK NHS hospital trusts with its anticipated results within few months. […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
